Your browser doesn't support javascript.
loading
The associations between central serous chorioretinopathy and muscle relaxants: A case-control study.
Jain, Manish; Garg, Sunir J; Khan, Mohammad; Chaudhary, Varun; Zeraatkar, Dena; Kurian, Dhanya; Lal, Sarath.
Afiliação
  • Jain M; Department of Ophthalmology, Veer Chandra Singh Garhwali, Government Institute of Medical Sciences and Research, Srinagar, Uttarakhand, India.
  • Garg SJ; Department of Ophthalmology, NMC Hospital, Al Ain, United Arab Emirates.
  • Khan M; Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • Chaudhary V; Department of Health Research Methods, Evidence and Impact, McMaster University, Ontario, Canada.
  • Zeraatkar D; Department of Surgery, Division of Ophthalmology, McMaster University, Hamilton, Ontario, Canada.
  • Kurian D; Department of Health Research Methods, Evidence and Impact, McMaster University, Ontario, Canada.
  • Lal S; Department of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts, USA.
Taiwan J Ophthalmol ; 12(4): 415-422, 2022.
Article em En | MEDLINE | ID: mdl-36660119
ABSTRACT

PURPOSE:

To evaluate the role of muscle-relaxants as risk factors for the development of central serous chorioretinopathy (CSC) - the second most common retinopathy in our settings; despite multiple risk factors seen in our patients, 21% were initially labelled as idiopathic. MATERIALS AND

METHODS:

Retrospective case-control study at a tertiary hospital in the United Arab Emirates, where we reviewed the medical records of 273 patients with CSC examined between 2010 and 2019 for use of muscle-relaxants including tolperisone/eperisone, carisoprodol and gabapentin/pregabalin within a year of onset/recurrence of the disease. Intake of drugs with known association with CSC (including corticosteroids/sympathomimetics) was also recorded. Two hundred eighty-six subjects with adverse events seen at the same institute during the same study period served as controls. Odds ratios, Chi-Square tests and multivariate logistic regression were carried out to determine any associations with the muscle-relaxants and other pharmacological confounders - corticosteroids/sympathomimetics.

RESULTS:

Muscle relaxants may increase the risk of CSC as evident on multivariate regression analysis (OR 2.55; confidence interval [CI] 1.208-5.413); the significance was retained on removing the 6 subjects who had corticosteroids/sympathomimetics (OR 2.30; CI 1.073-4.939). Univariate analysis yielded an OR of 2.52 for muscle relaxants (CI 1.2149-5.2276), 2.96 for eperisone/tolperisone (CI 1.3531-6.5038), and 6.26 for eperisone as an individual agent (CI 1.8146-21.6252).

CONCLUSION:

We found muscle relaxants to be associated factors of CSC regardless of inclusion of corticosteroids/sympathomimetics (P < 0.05). Among individual classes of muscle relaxants in this study, only eperisone/tolperisone posed a significant risk (P < 0.05). The vascular smooth muscle relaxation could be the possible mechanism that affects the choroidal blood flow and indirectly predisposes to CSC.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article